JPMorgan Chase & Co. Has $352,000 Position in Invesco Pharmaceuticals ETF (NYSEARCA:PJP)

JPMorgan Chase & Co. boosted its position in Invesco Pharmaceuticals ETF (NYSEARCA:PJP) by 241.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,046 shares of the company’s stock after purchasing an additional 2,862 shares during the quarter. JPMorgan Chase & Co. owned about 0.12% of Invesco Pharmaceuticals ETF worth $352,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Howe & Rusling Inc. acquired a new position in Invesco Pharmaceuticals ETF in the third quarter valued at about $48,000. FMR LLC increased its stake in shares of Invesco Pharmaceuticals ETF by 29.4% in the 3rd quarter. FMR LLC now owns 1,057 shares of the company’s stock valued at $92,000 after purchasing an additional 240 shares during the last quarter. Secure Asset Management LLC acquired a new position in shares of Invesco Pharmaceuticals ETF during the 3rd quarter worth $229,000. Arete Wealth Advisors LLC acquired a new stake in Invesco Pharmaceuticals ETF in the third quarter valued at about $402,000. Finally, HBW Advisory Services LLC bought a new position in Invesco Pharmaceuticals ETF in the third quarter valued at about $509,000.

Invesco Pharmaceuticals ETF Trading Up 0.1 %

Invesco Pharmaceuticals ETF stock opened at $86.11 on Thursday. The stock has a 50-day moving average price of $84.34 and a two-hundred day moving average price of $85.73. Invesco Pharmaceuticals ETF has a 12 month low of $75.33 and a 12 month high of $89.87. The company has a market capitalization of $291.91 million, a PE ratio of 21.48 and a beta of 0.61.

Invesco Pharmaceuticals ETF Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.